Binding of  125 I‐iodovinyltetrabenazine to CNS vesicular monoamine transport sites | Zendy

Kung MeiPing | Zendy; Canney Daniel J. | Zendy; Frederick Dana | Zendy; Zhuang Zheng | Zendy; Billings Jeffrey J. | Zendy; Kung Hank F. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Binding of 125 I‐iodovinyltetrabenazine to CNS vesicular monoamine transport sites

Author(s) -

Kung MeiPing,

Canney Daniel J.,

Frederick Dana,

Zhuang Zheng,

Billings Jeffrey J.,

Kung Hank F.

Publication year - 1994

Publication title -

synapse

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.809

H-Index - 106

eISSN - 1098-2396

pISSN - 0887-4476

DOI - 10.1002/syn.890180308

Subject(s) - tetrabenazine , monoamine neurotransmitter , in vitro , chemistry , ligand (biochemistry) , binding site , vesicular transport protein , vesicular monoamine transporter 2 , biophysics , pharmacology , neuroscience , biochemistry , biology , serotonin , receptor , vesicle , dopamine , membrane

Binding characteristics of a novel radioiodinated tetrabenazine (TBZ) analog (iodovinyltetrabenazine; 125 I‐TBZ‐Fraction I) were evaluated. In rat striatal homogenates, 125 I‐TBZ‐I displayed a pharmacological profile consistent with specific binding to vesicular monoamine transport (VMAT) sites. In vitro autoradiographic studies using rat brain sections; further demonstrated that 125 I‐TBZ‐I labeled the regions rich in VMAT sites, and it may be a useful marker for these sites. This novel radioiodinated ligand, with high specific activity and high binding affinity, may provide a powerful tool for the in vitro assessment of neuronal loss in various neurodegenerative diseases. © 1994 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research